Intelligence · Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring ≤24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.
-
US 7408075
Synthesis of phosphocholine ester derivatives and conjugates thereof
granted -
US 7407935
Ricin toxin A-chain fragment for use as a vaccine
granted -
US 7407664
Peptide vaccines against group A streptococci
granted -
US 7407658
Vaccines for blocking transmission of plasmodium vivax
granted -
US 7404961
Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
granted -
US 7402659
Thymic stromal lymphopoietin receptor molecules and uses thereof
granted -
US 7402567
Treatment of disease by inducing cell apoptosis
granted -
US 7399827
Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
granted -
US 7388089
Anti-arthropod vector vaccines method of selecting and uses thereof
granted -
US 7384978
Compounds and methods for delivery of prostacyclin analogs
granted -
US 7381405
Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer
granted -
US 7381744
Method of treating osteoporosis comprising vacuolar-type (H+)-ATPase-inhibiting compounds
granted -
US 7378093
Broadly cross-reactive neutralizing antibodies against Human Immunodeficiency Virus selected by Env-CD4-co-receptor complexes
granted -
US 7378097
Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
granted -
US 7378257
Bacterial superantigen vaccines
granted -
US 7378276
Method of inducing memory B cell development and terminal differentiation
granted -
US 7378403
Akt inhibitors, pharmaceutical compositions, and uses thereof
granted -
US 7378277
Methods and compositions for transforming dendritic cells and activating T cells
granted -
US 7374931
Vaccine against staphylococcus intoxication
granted -
US 7374872
CC chemokine receptor 5 DNA, new animal models and therapeutic agents for HIV infection
granted -
US 7374756
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
granted -
US 7375185
Cardiac myosin light chain kinase polypeptide, encoding nucleic acid, and methods of use
granted -
US 7375079
Previns as specific inhibitors and therapeutic agents for botulinum toxin B and tetanus neurotoxins
granted -
US 7371385
Method of treating immune pathologies with low dose estrogen
granted -
US 7371392
Cd40 ligand adjuvant for respiratory syncytial virus
granted -
US 7371572
Mouse titers after two immunizations with VLPs alone
granted -
US 7371821
Cloning and expression of the full length 110 kDa antigen of Orientia tsutsugamushi to be used as a vaccine component against scrub typhus
granted -
US 7371225
Method for convection enhanced delivery of therapeutic agents
granted -
US 7368114
Fusion protein including of CD4
granted -
US 7368110
Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
granted -
US 7368100
Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same
granted -
US 7368106
Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state
granted -
US 7368116
Method of enhancing a targeted immune response against tumors
granted -
US 7364719
Vasoregulating compounds and methods of their use
granted -
US 7365171
Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities
granted -
US 7361664
Vitamin D receptor antagonists and related compositions and methods of use
granted -
US 7361356
Self-assembling recombinant papillomavirus capsid proteins
granted -
US 7358377
Schweinfurthin analogues
granted -
US 7355012
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
granted -
US 7354904
Bacteriocin inducer peptides
granted -
US 7354711
Methods for inhibiting immunostimulatory DNA associated responses
granted -
US 7354909
Method for rapid generation of mature dendritic cells
granted -
US 7351403
Sunscreen reagents from unsaturated waxes and triglycerides
granted -
US 7351435
Deglycosylated ricin toxin a-chain vaccine
granted -
US 7348319
Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same
granted -
US 7341726
Modified HCV peptide immunogens
granted -
US 7339037
Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
granted -
US 7338807
Screening assays for compounds that cause apoptosis
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory